X
Adcetris cleared by NICE in aggressive blood cancer
https://pharmaphorum.com/news/takedas-adcetris-cleared-nhs-funding-aggressive-blood-cancer/
non-Hodgkin lymphoma
Kite and Fosun appoint leader for CAR-T debut in China
But rival Juno finally gives up on lead therapy.
J&J/AbbVie blood cancer drug gets fifth US indication
Imbruvica approved in marginal zone lymphoma.
Juno boosted by CAR-T trial findings in NHL
Biotech plans pivotal trial next year.
